The weekly litigation news digest is live. Subscribe now

IP Verse

Dosing Regimen For A Selective S1P1 Receptor Agonist - EP3256125

The patent EP3256125 was granted to Actelion Pharmaceuticals on Jan 26, 2022. The application was filed on Dec 10, 2015 under application number EP15807916A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3256125

ACTELION PHARMACEUTICALS
Application Number
EP15807916A
Filing Date
Dec 10, 2015
Status
Granted And Under Opposition
Dec 24, 2021
Publication Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
STADA ARZNEIMITTELOct 26, 2022HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSOct 21, 2022ELKINGTON AND FIFEADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2005054215
DESCRIPTIONWO2008062376
DESCRIPTIONWO2009115954
DESCRIPTIONWO2010046835
DESCRIPTIONWO2014027330
INTERNATIONAL-SEARCH-REPORTWO2009115954
OPPOSITIONWO2009115954

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents